Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic

Hypertension Research

Volumn 32, Issue 12, 2009, Pages 1086-1090

  Takami, Takeshi ^a  

^a Clinic Jingumae   (Japan)

Author keywords

Brachial ankle pulse wave velocity; Diuretics; Morning hypertension; Valsartan

Indexed keywords

TRICHLORMETHIAZIDE; VALSARTAN;

ADULT; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MALE; MORNING DOSAGE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SUPINE POSITION; TREATMENT DURATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANKLE BRACHIAL INDEX; BLOOD FLOW VELOCITY; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULSATILE FLOW; TETRAZOLES; TRICHLORMETHIAZIDE; VALINE;

EID: 73849117051     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2009.156     Document Type: Article

References (24)

1. Pickering TG, Eguchi K, Kario K. Masked hypertension: a review. Hypertens Res 2007; 30: 479-488.
2. Björklund K, Lind L, Zethelius B, Andrén B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 2003; 107: 1297-1302.
3. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
4. Tomiyama H, Koji Y, Yambe M, Shiina K, Motobe K, Yamada J, Shido N, Tanaka N, Chikamori T, Yamashina A. Brachial-ankle pulse wave velocity is a simple and independent predictor of prognosis in patients with acute coronary syndrome. Circ J 2005; 69: 815-822.
5. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, Hori S, Yamamoto Y. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003; 326: 1427-1431.
7. The Japanese Society of Hypertension, Guideline Making Committee for the Management of Hypertension (eds). Guidelines for the Management of Hypertension 2009 (JSH2009). Life Science Publisher: Tokyo, 2009.
8. The Japanese Society of Hypertension, (eds). Guideline for Measurement Conditions of Blood Pressure at Home. Life Science Publisher: Tokyo, 2003.
9. Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, Toyota T. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004; 17: 1050-1055.
10. Yamashina A, Tomiyama H, Arai T, Koji Y, Yambe M, Motobe H, Glunizia Z, Yamamoto Y, Hori S. Nomogram of the relation of brachial-ankle pulse wave velocity with blood pressure. Hypertens Res 2003; 26: 801-806.
11. Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, Menard J, Mallion JM. Cardiovascular prognosis of 'masked hypertension' detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342-1349.
12. Portaluppi F, Bagni B, degli Uberti E, Montanari L, Cavallini R, Trasforini G, Margutti A, Ferlini M, Zanella M, Parti M. Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects. J Hypertens 1990; 8: 85-95.
13. Hermida RC, Calvo C, Ayala DE, Doḿinguez MJ, Covelo M, Fernández JR, Mojón A, López JE. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 2003; 42: 283-290. (Pubitemid 37093474)
14. Ishikawa J, Kario K, Hoshide S, Eguchi K, Morinari M, Kaneda R, Umeda Y, Ishikawa S, Kuroda T, Hojo Y, Shimada K. Determinants of exaggerated difference in morning and evening blood pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi Morning Hypertension Research (J-MORE) Study. Am J Hypertens 2005; 18: 958-965.
15. Ishikawa J, Hoshide S, Shibasaki S, Matsui Y, Kabutoya T, Eguchi K, Ishikawa S, Pickering TG, Shimada K, Kario K. Relationship between morning hypertension identified by home blood pressure monitoring and brain natriuretic peptide and estimated glomerular filtration rate: the Japan Morning Surge 1 (JMS-1) Study. J Clin Hypertens (Greenwich) 2008; 10: 34-42.
16. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res 2003; 26: 609-614.
17. Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens 2002; 15: 1092-1095.
18. Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, Chikamori T, Hori S, Yamamoto Y, Doba N, Hinohara S. Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement-a survey of 12517 subjects. Atherosclerosis 2003; 166: 303-309.
19. Webster J, Newnham D, Petrie JC, Lovell HG. Influence of arm position on measurement of blood pressure. Br Med J 1984; 288: 1574-1575.
20. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003; 44: 884-890.
21. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensin- aldosterone system. J Renin Angiotensin Aldosterone Syst 2004; 5: 102-108.
22. Stergiou GS. Angiotensin receptor blockade in the challenging era of systolic hypertension. J Hum Hypertens 2004; 18: 837-847.
23. Yamashina A, Tomiyama H, Arai T, Hirose K, Koji Y, Hirayama Y, Yamamoto Y, Hori S. Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 2003; 26: 615-622.
24. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N. for Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439.